Scientists create innovative drug design strategy to improve breast cancer treatment

November 21, 2016, The Scripps Research Institute
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

While there have been advances in the treatment of hormone-driven breast cancer, resistance to these therapies remains a significant problem. Side effects, including an increased risk of uterine cancer among postmenopausal women, also severely curtail their use for prevention.

However, a new study by scientists from the Florida campus of The Scripps Research Institute (TSRI) offers a novel structure-based drug design strategy aimed at altering the basic landscape of this type of .

The findings show that the current approach is not the only, or even the best way, to block the .

"We have created a different approach that gives us a mechanism to produce new types of therapeutic molecules," said TSRI Associate Professor Kendall Nettles. "There are a lot of ways to avoid resistance and other cancer risks, and this gives us a tool box full of alternative approaches that could limit or eliminate those effects."

"With the standard method, no one understands the structural basis," he continued. "With our approach we know exactly how we did it. If you can see the shape of the receptor protein and see how the drug works on it, that makes the development process that much faster."

The findings were published November 21, 2016, by the journal Nature Chemical Biology.

Seeing Is Believing

The current method of creating this class of drugs, which includes tamoxifen, involves attaching a bulky cluster of atoms with a chainlike structure (called, appropriately, a side chain) to molecules that disrupt the estrogen receptor binding site.

The team's strategy taps a technique called x-ray crystallography to visualize the drug candidate as it binds to the receptor. This image is used to guide the production of estrogen receptor degraders that also lack the side chain, helping to reduce the risk of resistance and the development of other cancers.

"Our structure-trapping approach to X-ray crystallography provides a molecular snapshot of how subtle changes to a compound series generate a range of graded activity profiles," said Research Associate Jerome C. Nwachukwu, who was co-first author with Research Associate Sathish Srinivasan. "This structurally distinct mechanism, acting indirectly rather than involvement of the typical side chain, provides a new way to design biologically distinct molecules for prevention and treatment."

The new method also makes it possible to identify structural rules for how the molecules interact.

"This is the first example of a structure-based design strategy targeting the estrogen receptor where there is a clear correlation between the chemistry, crystal structure and activity, which is another big advance that will be of broad interest to the cancer community," Srinivasan said. "We show that indirect antagonism can result in inhibition of proliferation in a predictive fashion."

Explore further: Scientists predict cell changes that affect breast cancer growth, opening door to more effective therapies

More information: Full antagonism of the estrogen receptor without a prototypical ligand side chain, Nature Chemical Biology, nature.com/articles/doi:10.1038/nchembio.2236

Related Stories

Tamoxifen resistance linked to high estrogen levels in utero

September 8, 2016

An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals. The study provides a new path forward ...

Recommended for you

Sculpting stable structures in pure liquids

February 21, 2019

Oscillating flow and light pulses can be used to create reconfigurable architecture in liquid crystals. Materials scientists can carefully engineer concerted microfluidic flows and localized optothermal fields to achieve ...

LMC S154 is a symbiotic recurrent nova, study suggests

February 21, 2019

Astronomers have conducted observations of a symbiotic star in the Large Magellanic Cloud (LMC), known as LMC S154, which provide new insights about the nature of this object. Results of these observations, presented in a ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.